v3.25.4
Note 12 - Share-based Compensation
12 Months Ended
Dec. 31, 2025
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

12. SHARE-BASED COMPENSATION

 

On May 7, 2014, our shareholders approved the 2014 Omnibus Incentive Plan and in May 2021 this plan was amended as our shareholders authorized an additional 600,000 shares (as amended, the "2014 Plan"). The 2014 Plan included 1,100,000 of our common shares that may have been granted under various types of awards as described in the 2014 Plan. As of December 31, 2024, there were no shares authorized to issue under the 2014 Plan as the plan expired upon adoption of the 2024 Omnibus Incentive Plan.

 

On June 5, 2024, our shareholders approved the 2024 Omnibus Incentive Plan (the "2024 Plan"). The purpose of the 2024 Plan was to authorize shares to be available for grant upon expiration of the 2014 Plan and to make other design changes based on recent corporate governance and other trends. We carried over 472,862 shares that remained available under the 2014 Plan and our shareholders authorized an additional 27,138 shares for the 2024 Plan for a total of 500,000 shares eligible for grant under the 2024 Plan. As of December 31, 2025, we were authorized to issue 448,788 shares under the 2024 Plan.

 

During the years ended December 31, 2025 and 2024we issued 28,678 shares and 19,634 shares of common stock to members of our Board of Directors, respectively.

 

Stock Options 

 

There were no options granted for the year ended December 31, 2025 and 2024. 

 

For the years ended December 31, 2025 and 2024, we recognized share-based compensation expense and the corresponding tax benefit as follows:

 

($ in thousands)

 

2025

  

2024

 

Share-based compensation expense

 $1,617  $1,294 

Tax benefit

  272   220 

 

The following summarizes stock option activity for the year ended December 31, 2025:

 

          

Weighted

     
      

Weighted

  

Average

     
      

Average

  

Remaining

  

Aggregate

 

($ amounts are per share)

 

Shares

  

Exercise Price

  

Actual Term

  

Intrinsic Value

 

Options outstanding at January 1, 2025

  199,700  $28.82         

Issued

  -   -         

Exercised

  (31,800)  25.43         

Forfeited or expired

  (17,850)  28.18         

Options outstanding at December 31, 2025

  150,050  $29.62   3.5  $477,497 

Expected to vest

  16,900  $35.57   5.6  $7,686 

Exercisable at December 31, 2025

  133,150  $28.86   3.2  $469,811 

 

For the years ended December 31, 2025 and 2024, cash received for the exercise of stock options was approximately $0.8 million and $0.6 million, respectively.

 

Restricted Stock Units

 

Under the 2024 Omnibus Incentive Plan, restricted stock units  may be granted to certain eligible employees and officers in accordance with the applicable equity compensation agreements. Subject to participants' continued employment and other plan terms and conditions, the awards generally vest over three years. The fair value of each restricted stock unit is estimated based on the fair value of the Company's common stock on the date of the grant. 

 

The following table summarizes the status of the Company's restricted stock units and activity as of  December 31, 2025:

 

  

Restricted Stock Units

 
      

Weighted-Average Grant Date

 

($ amounts are per share)

 

Quantity

  

Fair Value Per Share

 

Nonvested at January 1, 2025

  53,423  $26.54 

Granted

  45,286   21.52 

Vested

  (652)  12.79 

Forfeited

  (635)  23.62 

Nonvested at December 31, 2025

  97,422  $24.32 

 

As of December 31, 2025, the total unrecognized compensation cost related to non-vested stock options and restricted stock units was approximately $1.0 million with a weighted-average expense recognition period of 1.5 years.